Manitoba treatments

ROCHE: Evrysdi – Risdiplam


Effective June 1st according to Bulletin 118, effective June 1st, 2022, EVRYSDIⓇ (risdiplam) will be covered through Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary (link). The specific criteria for reimbursement are in line with recommendations made by CADTH in 2021 and can be requested at the EDS office within Manitoba Health.

BIOGEN: Nusinersen – Spinraza


Initiation Criteria
1. Pre-symptomatic patients with two or three copies of the SMN2 gene, OR

2. Had the disease for <6 months, two copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age; OR 3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently.†

Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement on HINE-2, CHOP INTEND, or HFMSE, OR

2. For those symptomatic at initiation: no improvement in HINE-2, CHOP INTENT, or HFMSE, OR

3. Permanent invasive ventilation required

“Other patients who do not meet the expanded funding criteria may be considered in exceptional cases.”

NOVARTIS: Onasemnogene abeparvovec – Zolgensma



Cure SMA Canada Conference August 19 – 21, 20220 Montreal, Quebec Le Centre Sheraton Montréal 1201 Blvd Rene-Levesque West

‘This disease will slowly rob me of everything’: Why are Canadians living with rare diseases waiting for treatment?

COVID has proven we can quickly set up infrastructure without long-term clinical data. It’s time to do the same with rare diseases, says Durhane Wong-Rieger, president and CEO of Canadian Organization for Rare Disorders. Vanessa Hrvatin, Feb 28 2022 Sasha Kirkland, pictured with her husband, Mark and son Maks, lives with spinal muscular atrophy (SMA).…

Novartis Community Update


103-7134 VEDDER RD.


TOLL FREE 855.824.1277

BC 604.824.1277

FAX 604.824.1363


Please email Susi Vander Wyk at head office